Dynavax sees comparable safety between Heplisav, GSK's Engerix-B

03/23/2010 | Reuters

Dynavax Technologies said safety data show no difference in terms of autoimmune adverse events between those who got its hepatitis B vaccine candidate Heplisav and GlaxoSmithKline's recently approved Engerix-B. Dynavax said the study was intended for submission to the FDA in relation to a clinical hold that was lifted in September.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY